Rosenblatt analyst Barton Crockett raised the firm’s price target on Stagwell (STGW) to $9 from $8 and keeps a Buy rating on the shares. Stagwell returned to peer-high organic growth in Q3, the analyst tells investors in a research note. The firm says the pressure Friday on sector peers, tied to concerns over pharma advertising, should not apply to Stagwell, which sold off its pharma business a year ago.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on STGW:
- Stagwell Inc. Reports Strong Q3 2024 Results
- Stagwell backs FY24 adjusted EPS view 75c-88c, consensus 75c
- Stagwell reports Q3 adjusted EPS 22c, consensus 21c
- STGW Upcoming Earnings Report: What to Expect?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
